Galderma Group AG (GALDZ.XC)
Cboe UK · CHF · Healthcare · Drug Manufacturers - Specialty & Generic
CHF 187.90 (-1.75%) as of
Key statistics
- Market cap
- 44.08B
- P/E (TTM)
- 64.79
- EPS (TTM)
- 2.90
- Dividend yield
- 0.18%
- 52-week range
- 136.30 – 193.95
- Beta
- -0.05
- Revenue (TTM)
- 5.92B
- Profit margin
- 14.57%
- Volume
- 36.78k
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Zug, Switzerland
- Employees
- 7,676
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.